CP
Caligan Partners Portfolio holdings
AUM
$515M
This Quarter Return
+21.73%
1 Year Return
+70.09%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$120M
AUM Growth
–
Cap. Flow
+$120M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
99.9%
Holding
11
New
11
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Liquidia Corp
LQDA
|
$58.9M |
| 2 |
Anika Therapeutics
ANIK
|
$17.5M |
| 3 |
Evolus
EOLS
|
$13.1M |
| 4 |
ADMA Biologics
ADMA
|
$10.4M |
| 5 |
Standard BioTools
LAB
|
$10M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Liquidia Corp
LQDA
$2.38B
| $58.9M | 49% |
+9,243,627
| New | +$58.9M |
|
|
2
Anika Therapeutics
ANIK
$135M
| $17.5M | 14.58% |
+591,675
| New | +$17.5M |
|
|
3
Evolus
EOLS
$494M
| $13.1M | 10.88% |
+1,740,700
| New | +$13.1M |
|
|
4
ADMA Biologics
ADMA
$4.12B
| $10.4M | 8.64% |
+2,676,093
| New | +$10.4M |
|
|
5
Standard BioTools
LAB
$481M
| $10M | 8.35% |
+8,576,799
| New | +$10M |
|
|
VRNA
6
Verona Pharma
VRNA
$9.16B
| $4.78M | 3.98% |
+183,064
| New | +$4.78M |
|
|
SCTL
7
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $2.39M | 1.99% |
+1,603,214
| New | +$2.39M |
|
8
EyePoint Pharmaceuticals
EYPT
$797M
| $1.52M | 1.27% |
+435,298
| New | +$1.52M |
|
|
ALIM
9
DELISTED
Alimera Sciences, Inc.
ALIM
| $1.3M | 1.08% |
+478,777
| New | +$1.3M |
|
10
Jazz Pharmaceuticals
JAZZ
$7.75B
| $159K | 0.13% |
+1,000
| New | +$159K |
|
11
Agios Pharmaceuticals
AGIO
$2.19B
| $122K | 0.1% |
+4,333
| New | +$122K |
|